Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
University of Miami, Bascom Palmer Eye Institute, Miami, Florida Mid Atlantic Retina/ Wills Eye, Philadelphia, Pennsylvania Retina Foundation of the Southwest, Dallas, Texas University of Wisconsin, Madison, Wisconsin